|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: EHF |
Gene summary for EHF |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | EHF | Gene ID | 26298 |
| Gene name | ETS homologous factor | |
| Gene Alias | ESE3 | |
| Cytomap | 11p13 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q9NZC4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 26298 | EHF | GSM4909281 | Human | Breast | IDC | 4.09e-15 | -4.53e-01 | 0.21 |
| 26298 | EHF | GSM4909282 | Human | Breast | IDC | 1.50e-16 | -4.84e-01 | -0.0288 |
| 26298 | EHF | GSM4909285 | Human | Breast | IDC | 1.42e-03 | -1.95e-01 | 0.21 |
| 26298 | EHF | GSM4909286 | Human | Breast | IDC | 4.65e-07 | -3.41e-01 | 0.1081 |
| 26298 | EHF | GSM4909287 | Human | Breast | IDC | 8.86e-11 | -3.81e-01 | 0.2057 |
| 26298 | EHF | GSM4909290 | Human | Breast | IDC | 5.53e-04 | -3.25e-01 | 0.2096 |
| 26298 | EHF | GSM4909291 | Human | Breast | IDC | 2.62e-22 | -5.85e-01 | 0.1753 |
| 26298 | EHF | GSM4909293 | Human | Breast | IDC | 6.60e-03 | -2.20e-01 | 0.1581 |
| 26298 | EHF | GSM4909294 | Human | Breast | IDC | 8.16e-11 | -4.18e-01 | 0.2022 |
| 26298 | EHF | GSM4909296 | Human | Breast | IDC | 4.98e-07 | -1.47e-01 | 0.1524 |
| 26298 | EHF | GSM4909297 | Human | Breast | IDC | 4.36e-30 | -5.28e-01 | 0.1517 |
| 26298 | EHF | GSM4909298 | Human | Breast | IDC | 3.77e-16 | -4.40e-01 | 0.1551 |
| 26298 | EHF | GSM4909301 | Human | Breast | IDC | 6.98e-04 | -2.22e-01 | 0.1577 |
| 26298 | EHF | GSM4909302 | Human | Breast | IDC | 5.86e-14 | -4.00e-01 | 0.1545 |
| 26298 | EHF | GSM4909304 | Human | Breast | IDC | 8.76e-35 | -5.69e-01 | 0.1636 |
| 26298 | EHF | GSM4909306 | Human | Breast | IDC | 4.16e-18 | -4.37e-01 | 0.1564 |
| 26298 | EHF | GSM4909309 | Human | Breast | IDC | 4.67e-03 | -2.50e-01 | 0.0483 |
| 26298 | EHF | GSM4909311 | Human | Breast | IDC | 5.89e-26 | -4.24e-01 | 0.1534 |
| 26298 | EHF | GSM4909312 | Human | Breast | IDC | 2.24e-09 | -6.36e-02 | 0.1552 |
| 26298 | EHF | GSM4909313 | Human | Breast | IDC | 1.81e-02 | -2.34e-01 | 0.0391 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00506736 | Breast | Precancer | epithelial cell proliferation | 46/1080 | 437/18723 | 6.02e-05 | 1.23e-03 | 46 |
| GO:005067313 | Breast | IDC | epithelial cell proliferation | 60/1434 | 437/18723 | 7.13e-06 | 2.15e-04 | 60 |
| GO:005067322 | Breast | DCIS | epithelial cell proliferation | 57/1390 | 437/18723 | 2.22e-05 | 5.23e-04 | 57 |
| GO:00506737 | Cervix | CC | epithelial cell proliferation | 98/2311 | 437/18723 | 2.01e-09 | 2.15e-07 | 98 |
| GO:005067314 | Cervix | HSIL_HPV | epithelial cell proliferation | 34/737 | 437/18723 | 1.31e-04 | 2.61e-03 | 34 |
| GO:0050673 | Colorectum | AD | epithelial cell proliferation | 119/3918 | 437/18723 | 8.75e-04 | 8.51e-03 | 119 |
| GO:00506731 | Colorectum | MSS | epithelial cell proliferation | 108/3467 | 437/18723 | 6.76e-04 | 7.30e-03 | 108 |
| GO:00506732 | Colorectum | FAP | epithelial cell proliferation | 84/2622 | 437/18723 | 1.39e-03 | 1.25e-02 | 84 |
| GO:00506733 | Colorectum | CRC | epithelial cell proliferation | 69/2078 | 437/18723 | 1.61e-03 | 1.69e-02 | 69 |
| GO:00506738 | Endometrium | AEH | epithelial cell proliferation | 84/2100 | 437/18723 | 4.88e-07 | 1.94e-05 | 84 |
| GO:005067315 | Endometrium | EEC | epithelial cell proliferation | 83/2168 | 437/18723 | 3.38e-06 | 9.14e-05 | 83 |
| GO:005067318 | Esophagus | ESCC | epithelial cell proliferation | 238/8552 | 437/18723 | 1.19e-04 | 8.20e-04 | 238 |
| GO:00506735 | Lung | IAC | epithelial cell proliferation | 68/2061 | 437/18723 | 2.05e-03 | 2.05e-02 | 68 |
| GO:005067312 | Lung | AIS | epithelial cell proliferation | 62/1849 | 437/18723 | 2.26e-03 | 2.39e-02 | 62 |
| GO:005067310 | Oral cavity | OSCC | epithelial cell proliferation | 212/7305 | 437/18723 | 2.82e-05 | 2.61e-04 | 212 |
| GO:005067317 | Oral cavity | EOLP | epithelial cell proliferation | 75/2218 | 437/18723 | 5.90e-04 | 4.97e-03 | 75 |
| GO:005067323 | Oral cavity | NEOLP | epithelial cell proliferation | 73/2005 | 437/18723 | 7.74e-05 | 9.93e-04 | 73 |
| GO:00506739 | Prostate | BPH | epithelial cell proliferation | 116/3107 | 437/18723 | 7.12e-08 | 1.85e-06 | 116 |
| GO:005067316 | Prostate | Tumor | epithelial cell proliferation | 125/3246 | 437/18723 | 2.56e-09 | 1.08e-07 | 125 |
| GO:005067319 | Skin | AK | epithelial cell proliferation | 86/1910 | 437/18723 | 1.52e-09 | 1.43e-07 | 86 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| EHF | MAIT | Cervix | CC | DANT2,MFHAS1,MUC4, etc. | 8.21e-02 |  |
| EHF | STM | Endometrium | AEH | STK38L,ELF3,CYBA, etc. | 5.25e-01 |  |
| EHF | STM | Endometrium | Healthy | KRT18,PAX2,SCNN1A, etc. | 2.12e-01 |  |
| EHF | MDSC | Skin | ADJ | DSC3,DSP,KRT10, etc. | 2.00e-01 |  |
| EHF | CD8TRM | Skin | ADJ | DSC3,DSP,KRT10, etc. | 2.36e-02 | |
| EHF | MDSC | Skin | AK | DSC3,DSP,KRT10, etc. | 7.10e-01 |  |
| EHF | MDSC | Skin | cSCC | DSC3,DSP,KRT10, etc. | 7.93e-02 |  |
| EHF | CD8TRM | Skin | cSCC | DSC3,DSP,KRT10, etc. | 2.16e-01 | |
| EHF | MDSC | Skin | Healthy | DSC3,DSP,KRT10, etc. | 6.05e-02 |  |
| EHF | CD8TRM | Skin | SCCIS | DSC3,DSP,KRT10, etc. | 2.68e-02 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 2 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| EHF | SNV | Missense_Mutation | c.103C>G | p.Pro35Ala | p.P35A | Q9NZC4 | protein_coding | tolerated(0.34) | benign(0.001) | TCGA-A2-A0CU-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| EHF | deletion | Frame_Shift_Del | novel | c.669delG | p.Lys223AsnfsTer18 | p.K223Nfs*18 | Q9NZC4 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| EHF | SNV | Missense_Mutation | c.898N>T | p.Arg300Cys | p.R300C | Q9NZC4 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| EHF | SNV | Missense_Mutation | novel | c.674N>G | p.Asn225Ser | p.N225S | Q9NZC4 | protein_coding | tolerated(0.47) | benign(0.006) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| EHF | SNV | Missense_Mutation | c.898N>T | p.Arg300Cys | p.R300C | Q9NZC4 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A6-2682-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5 | PD | |
| EHF | SNV | Missense_Mutation | c.365C>T | p.Ala122Val | p.A122V | Q9NZC4 | protein_coding | tolerated(0.43) | benign(0.395) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| EHF | SNV | Missense_Mutation | c.122N>G | p.His41Arg | p.H41R | Q9NZC4 | protein_coding | tolerated(0.59) | benign(0.036) | TCGA-NH-A8F7-06 | Colorectum | NA | NA | NA | NA | NA | NA | NA | |
| EHF | deletion | Frame_Shift_Del | novel | c.664delN | p.Lys223SerfsTer18 | p.K223Sfs*18 | Q9NZC4 | protein_coding | TCGA-AA-3950-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| EHF | SNV | Missense_Mutation | c.910C>G | p.Arg304Gly | p.R304G | Q9NZC4 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-A5-A0GN-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| EHF | SNV | Missense_Mutation | c.365N>T | p.Ala122Val | p.A122V | Q9NZC4 | protein_coding | tolerated(0.43) | benign(0.395) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |